Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

The only two approved treatments for Alzheimer’s that can slow progression—developed by Eli Lilly and Biogen-Eisai—work by removing amyloid plaque. They reduce cognitive dec ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

New research suggests that Alzheimer's disease can be slowed, prevented, and even reversed through medication and lifestyle changes.

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Biogen, Eisai, and all other drug companies seeking FDA accelerated approval for a class of Alzheimer's drugs known as monoclonal antibodies would fall under Medicare's decision to pay for the ...

Eisai made history last year as Biogen’s partner on Aduhelm, the first approved Alzheimer’s treatment in decades. And yes, they know the launch could have gone better.

Eisai shares climbed 3.6% in Tokyo afternoon trade while Biogen shares were 0.9% higher in after-hours trade. They have jumped some 60% and 47% respectively since the announcement of the trial's ...

Biogen to manufacture new Alzheimer’s drug at RTP facility Alzheimer's biogen eisai PreviousLuxury homes – $2.5M or more – keep selling in Triangle, Triad despite souring economy ...